Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Starr Invests $20.5 Million in Techpool

publication date: Oct 14, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Starr International Finance AG, a Swiss private equity firm, has agreed to make a $20.5 million investment in Techpool Bio-Pharma Company, a Guangzhou pharmaceutical company that specializes in human urinary protein-based drugs. Starr will purchase 20 million new shares directly from Techpool for $14.6 million, and it will also acquire 8 million shares from Guangzhou Bopu Bio Technology, a Techpool shareholder. After the investment, Starr will own 28% of Techpool, which will become a foreign investment enterprise. More details...



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners